Circulating soluble Fas levels in patients with hepatitis C virus infection and interferon therapy

Journal of Gastroenterology

Volumn 39, Issue 12, 2004, Pages 1189-1195

  Kakiuchi, Yoshimi ^a   Yuki, Nobukazu ^a   Iyoda, Kenya ^a   Sugiyasu, Yasunori ^a   Kaneko, Akira ^a   Kato, Michio ^a  

^a OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

Apoptosis; Hepatitis C; Soluble Fas; Type 1 interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA INTERFERON; FAS ANTIGEN; INTERFERON; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; CELL PROTECTION; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE SEVERITY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER INJURY; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UPREGULATION; VIROLOGY; VIRUS CARRIER; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; INTERFERON-BETA; MALE; MIDDLE AGED;

EID: 11344285670     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-004-1470-2     Document Type: Article

References (18)

1. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994;19:1354-9.
2. Okazaki M, Hino K, Fujii K, Kobayashi N, Okita K. Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1996;41:2453-8.
3. Mita E, Hayashi N, Iio S, Takehara T, Hijioka T, Kasahara A, et al. Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 1994;204:468-74.
4. Kim HT, Stoica G, Bazer FW, Ott TL. Interferon tau-induced hepatocyte apoptosis in sheep. Hepatology 2000;31:1275-84.
5. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995;154:2706-13.
6. Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996;156:4622-30.
7. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-62.
8. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997;3:409-13.
9. Krams SM, Fox CK, Beatty PR, Cao S, Villanueva JC, Esquivel CO, et al. Human hepatocytes produce an isoform of Fas that inhibits apoptosis. Transplantation 1998;65:713-21.
10. Iio S, Hayashi N, Mita E, Ueda K, Mochizuki K, Hiramatsu N, et al. Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 1998;29:517-23.
11. Yoneyama K, Goto T, Miura K, Mikami K, Ohshima S, Nakane K, et al. The expression of Fas and Fas ligand, and the effects of interferon in chronic liver diseases with hepatitis C virus. Hepatol Res 2002;24:327-37.
12. Seishima M, Takemura M, Saito K, Sano H, Minatoguchi S, Fujiwara H, et al. Highly sensitive ELISA for soluble Fas in serum: Increased soluble Fas in the elderly. Clin Chem 1996;42: 1911-4.
13. Endo S, Inada K, Takakuwa T, Kasai T, Yamada Y, Wakabayashi G, et al. Nitrite/nitrate (NOx) and sFas antigen levels in patients with multiple organ failure. Res Commun Mol Pathol Pharmacol 1996;92:253-6.
14. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
15. Shiratori Y, Perelson AS, Weinberger L, Imazeki F, Yokosuka O, Nakata R, et al. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta. J Hepatol 2000;33:313-22.
16. Asahina Y, Izumi N, Uchihara M, Noguchi O, Tsuchiya K, Hamano K, et al. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. Hepatology 2001;34:377-84.
17. Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K, Barber GN. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J 1998;17:6888-902.
18. Donze O, Dostie J, Sonenberg N. Regulatable expression of the interferon-induced double-stranded RNA dependent protein kinase PKR induces apoptosis and Fas receptor expression. Virology 1999;256:322-9.